The drug is developed by NPS Pharmaceuticals.
If approved, Gattex would be the first FDA-approved therapy indicated for the long-term treatment of adults with short bowl syndrome, according to the release. The disorder prevents the body from absorbing enough nutrients and fluids through the gastrointestinal track.
The Prescription Drug User Fee Act date for FDA’s completion of review of the new drug application for Gattex is December 30.
NPS Pharmaceuticals is headquartered in Bedminster, N.J.
Related Articles on Gastroenterology:
Gastroenterologist on the Move: Dr. Andrew Pellecchia Joins NY’s Faxton St. Luke’s Healthcare
Gastroenterologist Dr. William Lipshutz to Receive ACP Teaching Award
Gastroenterologist on the Move: Dr. José Cabrera Joins Children’s Hospital of Wisconsin
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
